MN-AYMIUM
9.5.2022 12:02:04 CEST | Business Wire | Press release
Aymium , the leading producer of renewable biocarbon products, announced that it has entered a long-term supply contract for its patented, coal replacement product with Hokuriku Electric Power Company and Nippon Steel Trading . The contract is the largest for advanced biocarbon globally and will support the first large-scale continuous utility use of advanced biocarbon to replace coal in power generation. Aymium produces the only demonstrated carbon-negative product for replacing coal in power generation.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220509005317/en/
“Hokuriku’s pioneering use of Aymium’s leading-edge products to replace coal will accelerate transition away from fossil-fuel-based power generation and reduce environmental impacts,” said Aymium CEO James Mennell . “Aymium’s products allow immediate replacement of coal with a renewable, carbon-negative product. Our collaboration with Hokuriku and Nippon Steel Trading advances our shared mission of decarbonization and global environmental improvement.”
Each ton of Aymium’s product, when used in place of coal, results in a reduction of over 2.5 tons of CO2 as well as over 95% reduction in emission of other pollutants from coal-generated power, including sulfur dioxide and mercury.
The landmark contract and associated environmental benefits were celebrated by U.S. Ambassador to Japan Rahm Emanuel . “Hokuriku Electric Power’s agreement to purchase Aymium’s innovative renewable biocarbon products is a win for U.S. jobs, the environment, and U.S. exports. Japanese investment in Aymium’s innovative technology, from both Hokuriku Electric Power and Nippon Steel Trading, shows the power of U.S. – Japan cooperation,” said Ambassador Emanuel.
Aymium’s renewable product is created through a non-combustion process that converts biomass to high purity biocarbon and biogas, recovers and recycles water from the biomass, and is powered by self-generated renewable energy. The product has been tested at power-plant scale by Hokuriku, confirming suitability and advantages as a replacement for fossil coal.
“Hokuriku is committed to decarbonization, and strengthening our relationship with Aymium, whose patented technology shows high growth potential and contributes to Hokuriku’s efforts to become carbon neutral,” said Mr. Koji Matsuda, Executive President and Representative Director, Hokuriku Electric Power Company.
Hokuriku also announced an equity investment in Aymium. Hokuriku’s investment follows $200 million from investors by major global energy and metals companies with a focus on decarbonization, including Nippon Steel , Rio Tinto and Steel Dynamics .
“As partners to this contract, and investors in Aymium, Nippon Steel Trading is showing its commitment to advance carbon-reduction technologies that will have an immediate and near-term benefit,” said Mr. Yasumitsu Saeki, President and Representative Director, Nippon Steel Trading Corporation. Nippon Steel Trading is acting as Aymium’s and Hokuriku’s trading partner and managing international logistics for the supply to Hokuriku.
Aymium is a Minnesota-based cleantech company that creates renewable products that replace fossil fuels and reduce the environmental impact of large global industries including metals, energy, and crop production. Aymium’s products are protected by more than 275 issued and pending patents globally and are engineered to immediately displace fossil coal in energy production — without the need for any type of plant modifications. Aymium’s patented process converts certified sustainably sourced renewable biomass into biocarbon using integrated thermolysis.
Aymium is constructing two additional production facilities — one in Williams, California, and another in the Pacific Northwest — to produce advanced biocarbon for use by Hokuriku. Aymium anticipates investing over $350 million to construct the facilities that are scheduled to be operational in 2023.
Aymium produces high-value biocarbon and biohydrogen products that can be used to immediately replace fossil fuels in the production of metals, energy, crops, and in the purification of water and air with no modifications to equipment or processes. Produced using sustainably sourced biomass — recovered and unusable wood — Aymium’s bioproducts are renewable, carbon-negative, and they replace emission-heavy fossil fuels such as coal and coke. Aymium’s leading technology is backed by more than 275 issued or pending patents on a global basis. Aymium is headquartered in Minnesota.
About Hokuriku Electric Power Company
Established in 1951, Hokuriku Electric Power Company is a comprehensive energy company that aims to contribute to the development of the Hokuriku region through the stable supply of affordable and high-quality energy. The company's vision for the future is to “develop together with Hokuriku and deliver new value nationwide and overseas,” and it is expanding its business beyond the existing electric power business while contributing to social issues such as addressing the global warming, sustainable development of the region, and the realization of a smart society.
About Nippon Steel Trading Corporation
Nippon Steel Trading Corporation is the core trading company of NIPPON STEEL CORPORATION Group, and was established in October 2013 through the merger of Nippon Steel Trading Co., Ltd. and Sumikin Bussan Corporation. The company continues to grow as a multiple specialty trading company operating four integrated core businesses: steel, industrial supply & infrastructure, textiles, and foodstuffs.
Forward-Looking Statements
This press release contains some predictive statements about future events, including statements related to new facilities and environmental impact. These statements, which are generally preceded or accompanied by such typical conditional words as "anticipate", "intend", "believe", "estimate", "plan", "seek", "project", or "expect", or by the words "may", "will", or "should", are intended to be made as "forward-looking," subject to many risks and uncertainties, within the safe harbor protections of the Private Securities Litigation Reform Act of 1995. These statements speak only as of this date and are based upon currently available information and assumptions, which we consider reasonable as of this date. Such predictive statements are not a guarantee of future performance, and we undertake no duty to update or revise any such statements. There are many factors that could cause such forward-looking statements to turn out differently than anticipated.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220509005317/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
